Search

Your search keyword '"Labots, Mariette"' showing total 228 results
Start Over Author "Labots, Mariette"
228 results on '"Labots, Mariette"'

2. Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma

Author

Verheijden, Rik J., Burgers, Femke H., Janssen, Josephine C., Putker, Anouk E., Veenstra, Sophie P.G.R., Hospers, Geke A.P., Aarts, Maureen J.B., Hehenkamp, Karel W., Doornebosch, Veerle L.E., Verhaert, Marthe, van den Berkmortel, Franchette W.P.J., Chatzidionysiou, Katerina, Llobell, Arturo, Barros, Milton, Maria, Alexandre T.J., Takeji, Akari, García Morillo, José-Salvador, Lidar, Merav, van Eijs, Mick J.M., Blank, Christian U., Aspeslagh, Sandrine, Piersma, Djura, Kapiteijn, Ellen, Labots, Mariette, Boers-Sonderen, Marye J., van der Veldt, Astrid A.M., Haanen, John B.A.G., May, Anne M., and Suijkerbuijk, Karijn P.M.

Published
2024
Full Text
View/download PDF

3. Baseline tumor-infiltrating lymphocyte patterns and response to immune checkpoint inhibition in metastatic cutaneous melanoma

Author

van Duin, Isabella A.J., Schuiveling, Mark, ter Maat, Laurens S., van Amsterdam, Wouter A.C., van den Berkmortel, Franchette, Boers-Sonderen, Marye, de Groot, Jan Willem B., Hospers, Geke A.P., Kapiteijn, Ellen, Labots, Mariette, Piersma, Djura, Schrader, Anne M.R., Vreugdenhil, Gerard, Westgeest, Hans, Veta, Mitko, Blokx, Willeke A.M., van Diest, Paul J., and Suijkerbuijk, Karijn P.M.

Published
2024
Full Text
View/download PDF

4. Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol

Author

Verkerk, Karlijn, Geurts, Birgit S., Zeverijn, Laurien J., van der Noort, Vincent, Verheul, Henk M.W., Haanen, John B.A.G., van der Veldt, Astrid A.M., Eskens, Ferry A.L.M., Aarts, Maureen J.B., van Herpen, Carla M.L., Jalving, Mathilde, Gietema, Jourik A., Devriese, Lot A., Labots, Mariette, Barjesteh van Waalwijk van Doorn-Khosrovani, Sahar, Smit, Egbert F., and Bloemendal, Haiko J.

Published
2024
Full Text
View/download PDF

5. Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma

Author

Leek, Lindsay V. M., Notohardjo, Jessica C. L., de Joode, Karlijn, Velker, Eline L., Haanen, John B. A. G., Suijkerbuijk, Karijn P. M., Aarts, Maureen J. B., de Groot, Jan Willem B., Kapiteijn, Ellen, van den Berkmortel, Franchette W. P. J., Westgeest, Hans M., de Gruijl, Tanja D., Retel, Valesca P., Cuppen, Edwin, van der Veldt, Astrid A. M., Labots, Mariette, Voest, Emile E., van de Haar, Joris, and van den Eertwegh, Alfons J. M.

Published
2024
Full Text
View/download PDF

7. Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy

Author

Geurts, Birgit S, primary, Zeverijn, Laurien J, additional, van Berge Henegouwen, Jade M, additional, van der Wijngaart, Hanneke, additional, Hoes, Louisa R, additional, de Wit, Gijs F, additional, Spiekman, Ilse AC, additional, Battaglia, Thomas W, additional, van Beek, Daphne M, additional, Roepman, Paul, additional, Jansen, Anne ML, additional, de Leng, Wendy WJ, additional, Broeks, Annegien, additional, Labots, Mariette, additional, van Herpen, Carla ML, additional, Gelderblom, Hans, additional, Verheul, Henk MW, additional, Snaebjornsson, Petur, additional, and Voest, Emile E, additional

Published
2024
Full Text
View/download PDF

9. Evaluation of the Khorana, PROTECHT, and 5‐SNP scores for prediction of venous thromboembolism in patients with cancer

Author

Guman, Noori A.M., van Geffen, Roos J., Mulder, Frits I., van Haaps, Thijs F., Hovsepjan, Vahram, Labots, Mariette, Cirkel, Geert A., de Vos, Filip Y.F.L., Ten Tije, Albert J., Beerepoot, Laurens V., Tjan‐Heijnen, Vivianne C.G., van Laarhoven, Hanneke W.M., Hamberg, Paul, Vulink, Annelie J.E., Los, Maartje, Zwinderman, Aeilko H., Ferwerda, Bart, Lolkema, Martijn P.J.K., Steeghs, Neeltje, Büller, Harry R., Kamphuisen, Pieter W., and van Es, Nick

Published
2021
Full Text
View/download PDF

13. Time dependent effect of cold ischemia on the phosphoproteome and protein kinase activity in fresh-frozen colorectal cancer tissue obtained from patients

Author

Buffart, Tineke E., van den Oord, Rosanne A. H. M., van den Berg, Adriënne, Hilhorst, Riet, Bastiaensen, Niek, Pruijt, Hans F. M., van den Brule, Adriaan, Nooijen, Peet, Labots, Mariette, de Goeij-de Haas, Richard R., Dekker, Henk, Piersma, Sander R., Pham, Thang V., van der Leij, Theo, de Wijn, Rik, Ruijtenbeek, Rob, Jiménez, Connie R., and Verheul, Henk M. W.

Published
2021
Full Text
View/download PDF

15. Baseline tumor-infiltrating lymphocyte patterns and response to immune checkpoint inhibition in metastatic cutaneous melanoma

Author

van Duin, Isabella AJ, primary, Schuiveling, Mark, additional, ter Maat, Laurens S, additional, van Amsterdam, Wouter AC, additional, van den Berkmortel, Franchette, additional, Boers-Sonderen, Marye, additional, de Groot, Jan Willem B, additional, Hospers, Geke AP, additional, Kapiteijn, Ellen, additional, Labots, Mariette, additional, Piersma, Djura, additional, Schrader, Anne MR, additional, Vreugdenhil, Gerard, additional, Westgeest, Hans, additional, Veta, Mitko, additional, Blokx, Willeke AM, additional, van Diest, Paul J, additional, and Suijkerbuijk, Karijn PM, additional

Published
2023
Full Text
View/download PDF

17. Pan-cancer whole-genome analyses of metastatic solid tumours

Author

Priestley, Peter, Baber, Jonathan, Lolkema, Martijn P., Steeghs, Neeltje, de Bruijn, Ewart, Shale, Charles, Duyvesteyn, Korneel, Haidari, Susan, van Hoeck, Arne, Onstenk, Wendy, Roepman, Paul, Voda, Mircea, Bloemendal, Haiko J., Tjan-Heijnen, Vivianne C. G., van Herpen, Carla M. L., Labots, Mariette, Witteveen, Petronella O., Smit, Egbert F., Sleijfer, Stefan, Voest, Emile E., and Cuppen, Edwin

Published
2019
Full Text
View/download PDF

18. The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies

Author

Angus, Lindsay, Smid, Marcel, Wilting, Saskia M., van Riet, Job, Van Hoeck, Arne, Nguyen, Luan, Nik-Zainal, Serena, Steenbruggen, Tessa G., Tjan-Heijnen, Vivianne C. G., Labots, Mariette, van Riel, Johanna M. G. H., Bloemendal, Haiko J., Steeghs, Neeltje, Lolkema, Martijn P., Voest, Emile E., van de Werken, Harmen J. G., Jager, Agnes, Cuppen, Edwin, Sleijfer, Stefan, and Martens, John W. M.

Published
2019
Full Text
View/download PDF

19. Phosphoproteomics of patient-derived xenographs identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer

Author

Beekhof, Robin, primary, Bertotti, Andrea, additional, Böttger, Franziska, additional, Vurchio, Valentina, additional, Cottino, Francesca, additional, Zanella, Eugenia R., additional, Migliardi, Giorgia, additional, Viviani, Marco, additional, Grassi, Elena, additional, Lupo, Barbara, additional, Henneman, Alex A., additional, Knol, Jaco C., additional, Pham, Thang V., additional, de Goeij-de Haas, Richard, additional, Piersma, Sander R., additional, Labots, Mariette, additional, Verheul, Henk M.W., additional, Trusolino, Livio, additional, and Jimenez, Connie R., additional

Published
2023
Full Text
View/download PDF

21. Abstract CT139: The STELLAR trial: A phase II/III study of high-dose intermittent sunitinib in patients with recurrent glioblastoma

Author

Janssen, Jorien B., primary, Brahm, Cyrillo, additional, Driessen, Chantal M., additional, Nuver, Janine, additional, Labots, Mariette, additional, Kouwenhoven, Mathilde C., additional, Aliaga, Esther S., additional, Enting, Roelien H., additional, de Groot, Jan Cees, additional, Berkhof, Johannes, additional, Walenkamp, Annemiek M., additional, Verheul, Henk M., additional, and van Linde, Myra E., additional

Published
2023
Full Text
View/download PDF

22. Supplementary Legend from Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types

Author

van der Wijngaart, Hanneke, primary, Hoes, Louisa R., primary, van Berge Henegouwen, J. Maxime, primary, van der Velden, Daphne L., primary, Zeverijn, Laurien J., primary, Roepman, Paul, primary, van Werkhoven, Erik, primary, de Leng, Wendy W.J., primary, Jansen, Anne M.L., primary, Mehra, Niven, primary, Robbrecht, Debbie G.J., primary, Labots, Mariette, primary, de Groot, Derk Jan A., primary, Hoeben, Ann, primary, Hamberg, Paul, primary, Gelderblom, Hans, primary, Voest, Emile E., primary, and Verheul, Henk M.W., primary

Published
2023
Full Text
View/download PDF

23. Data from Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance

Author

Gotink, Kristy J., primary, Broxterman, Henk J., primary, Labots, Mariette, primary, de Haas, Richard R., primary, Dekker, Henk, primary, Honeywell, Richard J., primary, Rudek, Michelle A., primary, Beerepoot, Laurens V., primary, Musters, René J., primary, Jansen, Gerrit, primary, Griffioen, Arjan W., primary, Assaraf, Yehuda G., primary, Pili, Roberto, primary, Peters, Godefridus J., primary, and Verheul, Henk M.W., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Table from Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment

Author

Hoes, Louisa R., primary, van Berge Henegouwen, Jade M., primary, van der Wijngaart, Hanneke, primary, Zeverijn, Laurien J., primary, van der Velden, Daphne L., primary, van de Haar, Joris, primary, Roepman, Paul, primary, de Leng, Wendy J., primary, Jansen, Anne M.L., primary, van Werkhoven, Erik, primary, van der Noort, Vincent, primary, Huitema, Alwin D.R., primary, Gort, Eelke H., primary, de Groot, Jan Willem B., primary, Kerver, Emile D., primary, de Groot, Derk Jan, primary, Erdkamp, Frans, primary, Beerepoot, Laurens V., primary, Hendriks, Mathijs P., primary, Smit, Egbert F., primary, van der Graaf, Winette T.A., primary, van Herpen, Carla M.L., primary, Labots, Mariette, primary, Hoeben, Ann, primary, Morreau, Hans, primary, Lolkema, Martijn P., primary, Cuppen, Edwin, primary, Gelderblom, Hans, primary, Verheul, Henk M.W., primary, and Voest, Emile E., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma

Author

van Linde, Myra E., primary, Labots, Mariette, primary, Brahm, Cyrillo G., primary, Hovinga, Koos E., primary, De Witt Hamer, Philip C., primary, Honeywell, Richard J., primary, de Goeij-de Haas, Richard, primary, Henneman, Alex A., primary, Knol, Jaco C., primary, Peters, Godefridus J., primary, Dekker, Henk, primary, Piersma, Sander R., primary, Pham, Thang V., primary, Vandertop, William P., primary, Jiménez, Connie R., primary, and Verheul, Henk M.W., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figures 1-3 from Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance

Author

Gotink, Kristy J., primary, Broxterman, Henk J., primary, Labots, Mariette, primary, de Haas, Richard R., primary, Dekker, Henk, primary, Honeywell, Richard J., primary, Rudek, Michelle A., primary, Beerepoot, Laurens V., primary, Musters, René J., primary, Jansen, Gerrit, primary, Griffioen, Arjan W., primary, Assaraf, Yehuda G., primary, Pili, Roberto, primary, Peters, Godefridus J., primary, and Verheul, Henk M.W., primary

Published
2023
Full Text
View/download PDF

27. Data from Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment

Author

Hoes, Louisa R., primary, van Berge Henegouwen, Jade M., primary, van der Wijngaart, Hanneke, primary, Zeverijn, Laurien J., primary, van der Velden, Daphne L., primary, van de Haar, Joris, primary, Roepman, Paul, primary, de Leng, Wendy J., primary, Jansen, Anne M.L., primary, van Werkhoven, Erik, primary, van der Noort, Vincent, primary, Huitema, Alwin D.R., primary, Gort, Eelke H., primary, de Groot, Jan Willem B., primary, Kerver, Emile D., primary, de Groot, Derk Jan, primary, Erdkamp, Frans, primary, Beerepoot, Laurens V., primary, Hendriks, Mathijs P., primary, Smit, Egbert F., primary, van der Graaf, Winette T.A., primary, van Herpen, Carla M.L., primary, Labots, Mariette, primary, Hoeben, Ann, primary, Morreau, Hans, primary, Lolkema, Martijn P., primary, Cuppen, Edwin, primary, Gelderblom, Hans, primary, Verheul, Henk M.W., primary, and Voest, Emile E., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figure from Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment

Author

Hoes, Louisa R., primary, van Berge Henegouwen, Jade M., primary, van der Wijngaart, Hanneke, primary, Zeverijn, Laurien J., primary, van der Velden, Daphne L., primary, van de Haar, Joris, primary, Roepman, Paul, primary, de Leng, Wendy J., primary, Jansen, Anne M.L., primary, van Werkhoven, Erik, primary, van der Noort, Vincent, primary, Huitema, Alwin D.R., primary, Gort, Eelke H., primary, de Groot, Jan Willem B., primary, Kerver, Emile D., primary, de Groot, Derk Jan, primary, Erdkamp, Frans, primary, Beerepoot, Laurens V., primary, Hendriks, Mathijs P., primary, Smit, Egbert F., primary, van der Graaf, Winette T.A., primary, van Herpen, Carla M.L., primary, Labots, Mariette, primary, Hoeben, Ann, primary, Morreau, Hans, primary, Lolkema, Martijn P., primary, Cuppen, Edwin, primary, Gelderblom, Hans, primary, Verheul, Henk M.W., primary, and Voest, Emile E., primary

Published
2023
Full Text
View/download PDF

29. Supplementary Table 1 from Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types

Author

van der Wijngaart, Hanneke, primary, Hoes, Louisa R., primary, van Berge Henegouwen, J. Maxime, primary, van der Velden, Daphne L., primary, Zeverijn, Laurien J., primary, Roepman, Paul, primary, van Werkhoven, Erik, primary, de Leng, Wendy W.J., primary, Jansen, Anne M.L., primary, Mehra, Niven, primary, Robbrecht, Debbie G.J., primary, Labots, Mariette, primary, de Groot, Derk Jan A., primary, Hoeben, Ann, primary, Hamberg, Paul, primary, Gelderblom, Hans, primary, Voest, Emile E., primary, and Verheul, Henk M.W., primary

Published
2023
Full Text
View/download PDF

30. Supplementary Figure 1 from Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types

Author

van der Wijngaart, Hanneke, primary, Hoes, Louisa R., primary, van Berge Henegouwen, J. Maxime, primary, van der Velden, Daphne L., primary, Zeverijn, Laurien J., primary, Roepman, Paul, primary, van Werkhoven, Erik, primary, de Leng, Wendy W.J., primary, Jansen, Anne M.L., primary, Mehra, Niven, primary, Robbrecht, Debbie G.J., primary, Labots, Mariette, primary, de Groot, Derk Jan A., primary, Hoeben, Ann, primary, Hamberg, Paul, primary, Gelderblom, Hans, primary, Voest, Emile E., primary, and Verheul, Henk M.W., primary

Published
2023
Full Text
View/download PDF

31. Advancing wide implementation of precision oncology: A liquid nitrogen‐free snap freezer preserves molecular profiles of biological samples

Author

van der Wijngaart, Hanneke, primary, Jagga, Sahil, additional, Dekker, Henk, additional, de Goeij, Richard, additional, Piersma, Sander R., additional, Pham, Thang V., additional, Knol, Jaco C., additional, Zonderhuis, Babs M., additional, Holland, Harry J., additional, Jiménez, Connie R., additional, Verheul, Henk M. W., additional, Vanapalli, Srinivas, additional, and Labots, Mariette, additional

Published
2023
Full Text
View/download PDF

32. Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours

Author

Geurts, Birgit S., primary, Battaglia, Thomas W., additional, van Berge Henegouwen, J. Maxime, additional, Zeverijn, Laurien J., additional, de Wit, Gijs F., additional, Hoes, Louisa R., additional, van der Wijngaart, Hanneke, additional, van der Noort, Vincent, additional, Roepman, Paul, additional, de Leng, Wendy W. J., additional, Jansen, Anne M. L., additional, Opdam, Frans L., additional, de Jonge, Maja J. A., additional, Cirkel, Geert A., additional, Labots, Mariette, additional, Hoeben, Ann, additional, Kerver, Emile D., additional, Bins, Adriaan D., additional, Erdkamp, Frans G.L., additional, van Rooijen, Johan M., additional, Houtsma, Danny, additional, Hendriks, Mathijs P., additional, de Groot, Jan-Willem B., additional, Verheul, Henk M. W., additional, Gelderblom, Hans, additional, and Voest, Emile E., additional

Published
2023
Full Text
View/download PDF

33. Frequency of measuring body weight in (sub)populations of patients with cancer treated with chemotherapy

Author

Kemps, Shirley, Soleyman, Mostafa, Huls, Harmen, Labots, Mariette, and Crul, Mirjam

Abstract

ObjectivesMost cytostatics used in cancer treatment are dosed on body surface area (BSA). To administer an appropriate dose it is therefore necessary to know the patient’s correct body weight. However, evidence is lacking on how often, after initiation of treatment, body weight should be measured to recalculate BSA. We aimed to assess the relevance of weight measurements during chemotherapy treatment.MethodsOver a 2 year period we analysed BSA changes in adult patients undergoing chemotherapy treatment. The frequency of and median time to ≥10% BSA change was determined. We assumed a 10% BSA change required dose adjustment and was therefore clinically relevant.ResultsUsing a database query, data from 2276 patients were used for descriptive statistics, life table analyses and generalised estimating equations. The frequency of ≥10% BSA change occurred in a maximum of 7.6% of the patients, depending on the tumour type. Descriptive statistics in the indications with more than 100 patients showed that BSA changes of ≥10% occurred after 84 days. The groups with the earliest BSA changes were patients with acute leukaemia, lymphoma and pancreatic cancer.ConclusionsOur observations from real-world data indicate it is safe to omit the current requirement for monthly weight measurements. We advise that during chemotherapy, measuring the body weight in patients who have acute leukaemia, lymphoma or pancreatic cancer or who are under 20 years of age, should be performed at least every 3 months. For other patients, extending this period to a 6-monthly weight measurement should be considered.

Published
2024
Full Text
View/download PDF

35. High-Dose Intermittent Treatment with the Multikinase Inhibitor Sunitinib Leads to High Intra-Tumor Drug Exposure in Patients with Advanced Solid Tumors

Author

Gerritse, Sophie L., primary, Labots, Mariette, additional, Heine, Rob Ter, additional, Dekker, Henk, additional, Poel, Dennis, additional, Tauriello, Daniele V. F., additional, Nagtegaal, Iris D., additional, Van Den Hombergh, Erik, additional, Van Erp, Nielka, additional, and Verheul, Henk M. W., additional

Published
2022
Full Text
View/download PDF

36. Additional file 2 of Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours

Author

Geurts, Birgit S., Battaglia, Thomas W., van Berge Henegouwen, J. Maxime, Zeverijn, Laurien J., de Wit, Gijs F., Hoes, Louisa R., van der Wijngaart, Hanneke, van der Noort, Vincent, Roepman, Paul, de Leng, Wendy W. J., Jansen, Anne M. L., Opdam, Frans L., de Jonge, Maja J. A., Cirkel, Geert A., Labots, Mariette, Hoeben, Ann, Kerver, Emile D., Bins, Adriaan D., Erdkamp, Frans G.L., van Rooijen, Johan M., Houtsma, Danny, Hendriks, Mathijs P., de Groot, Jan-Willem B., Verheul, Henk M. W., Gelderblom, Hans, and Voest, Emile E.

Abstract

Additional file 2.

Published
2023
Full Text
View/download PDF

39. Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma

Author

van Linde, Myra E., Labots, Mariette, Brahm, Cyrillo G., Hovinga, Koos E., de Witt Hamer, Philip C., Honeywell, Richard J., de Goeij-de Haas, Richard, Henneman, Alex A., Knol, Jaco C., Peters, Godefridus J., Dekker, Henk, Piersma, Sander R., Pham, Thang V., Vandertop, William P., Jiménez, Connie R., Verheul, Henk M. W., ANS - Systems & Network Neuroscience, ANS - Neurovascular Disorders, Neurosurgery, CCA - Cancer biology and immunology, CCA - Imaging and biomarkers, Internal medicine, CCA - Treatment and quality of life, Amsterdam Neuroscience - Systems & Network Neuroscience, Clinical pharmacology and pharmacy, Medical oncology laboratory, Amsterdam Neuroscience - Neurovascular Disorders, Amsterdam Neuroscience - Neurodegeneration, and CCA - Cancer Treatment and quality of life

Subjects
Proteomics, Cancer Research, Indoles, Brain Neoplasms, urologic and male genital diseases, female genital diseases and pregnancy complications, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], All institutes and research themes of the Radboud University Medical Center, Oncology, Cell Line, Tumor, Sunitinib, Humans, Pyrroles, Glioblastoma
Abstract

Purpose: Tyrosine kinase inhibitors (TKI) have poor efficacy in patients with glioblastoma (GBM). Here, we studied whether this is predominantly due to restricted blood–brain barrier penetration or more to biological characteristics of GBM. Patients and Methods: Tumor drug concentrations of the TKI sunitinib after 2 weeks of preoperative treatment was determined in 5 patients with GBM and compared with its in vitro inhibitory concentration (IC50) in GBM cell lines. In addition, phosphotyrosine (pTyr)-directed mass spectrometry (MS)-based proteomics was performed to evaluate sunitinib-treated versus control GBM tumors. Results: The median tumor sunitinib concentration of 1.9 μmol/L (range 1.0–3.4) was 10-fold higher than in concurrent plasma, but three times lower than sunitinib IC50s in GBM cell lines (median 5.4 μmol/L, 3.0–8.5; P = 0.01). pTyr-phosphoproteomic profiles of tumor samples from 4 sunitinib-treated versus 7 control patients revealed 108 significantly up- and 23 downregulated (P < 0.05) phosphopeptides for sunitinib treatment, resulting in an EGFR-centered signaling network. Outlier analysis of kinase activities as a potential strategy to identify drug targets in individual tumors identified nine kinases, including MAPK10 and INSR/IGF1R. Conclusions: Achieved tumor sunitinib concentrations in patients with GBM are higher than in plasma, but lower than reported for other tumor types and insufficient to significantly inhibit tumor cell growth in vitro. Therefore, alternative TKI dosing to increase intratumoral sunitinib concentrations might improve clinical benefit for patients with GBM. In parallel, a complex profile of kinase activity in GBM was found, supporting the potential of (phospho)proteomic analysis for the identification of targets for (combination) treatment.

Published
2022

40. Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment

Author

Hoes, Louisa R., primary, van Berge Henegouwen, Jade M., additional, van der Wijngaart, Hanneke, additional, Zeverijn, Laurien J., additional, van der Velden, Daphne L., additional, van de Haar, Joris, additional, Roepman, Paul, additional, de Leng, Wendy J., additional, Jansen, Anne M.L., additional, van Werkhoven, Erik, additional, van der Noort, Vincent, additional, Huitema, Alwin D.R., additional, Gort, Eelke H., additional, de Groot, Jan Willem B., additional, Kerver, Emile D., additional, de Groot, Derk Jan, additional, Erdkamp, Frans, additional, Beerepoot, Laurens V., additional, Hendriks, Mathijs P., additional, Smit, Egbert F., additional, van der Graaf, Winette T.A., additional, van Herpen, Carla M.L., additional, Labots, Mariette, additional, Hoeben, Ann, additional, Morreau, Hans, additional, Lolkema, Martijn P., additional, Cuppen, Edwin, additional, Gelderblom, Hans, additional, Verheul, Henk M.W., additional, and Voest, Emile E., additional

Published
2022
Full Text
View/download PDF

41. Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types

Author

van der Wijngaart, Hanneke, primary, Hoes, Louisa R., additional, van Berge Henegouwen, J. Maxime, additional, van der Velden, Daphne L., additional, Zeverijn, Laurien J., additional, Roepman, Paul, additional, van Werkhoven, Erik, additional, de Leng, Wendy W.J., additional, Jansen, Anne M.L., additional, Mehra, Niven, additional, Robbrecht, Debbie G.J., additional, Labots, Mariette, additional, de Groot, Derk Jan A., additional, Hoeben, Ann, additional, Hamberg, Paul, additional, Gelderblom, Hans, additional, Voest, Emile E., additional, and Verheul, Henk M.W., additional

Published
2021
Full Text
View/download PDF

44. Additional file 4 of Time dependent effect of cold ischemia on the phosphoproteome and protein kinase activity in fresh-frozen colorectal cancer tissue obtained from patients

Author

Buffart, Tineke E., Oord, Rosanne A. H. M. Van Den, Berg, Adriënne Van Den, Hilhorst, Riet, Bastiaensen, Niek, Pruijt, Hans F. M., Brule, Adriaan Van Den, Nooijen, Peet, Labots, Mariette, Haas, Richard R. De Goeij-De, Dekker, Henk, Piersma, Sander R., Pham, Thang V., Leij, Theo Van Der, Wijn, Rik De, Ruijtenbeek, Rob, Jiménez, Connie R., and Verheul, Henk M. W.

Subjects
sense organs
Abstract

Additional file 4: Table S1. Peptides significantly changing with 180 min of CIT (p 2), measured with a peptide microarray for patients 1–4 using a One-Way ANOVA test. In patient 5 none of the peptides were significantly changing with CIT. Peptides significantly altered, in patients 1–5 combined using a Mixed Model analysis, are shown in bold. UniProt Accession numbers, protein IDs and peptide sequence are given. Table S2. Phosphopeptides significantly changing with CIT (p

Published
2021
Full Text
View/download PDF

45. Prediction of response to sunitinib in patients with advanced renal cell carcinoma (RCC) using mass spectrometry-based (phospho) proteomics.

Author

van der Wijngaart, Hanneke, primary, Beekhof, Robin, additional, Knol, Jaco C., additional, Henneman, Alex A., additional, de Goeij - de Haas, Richard, additional, Piersma, Sander R., additional, Pham, Thang V., additional, Jimenez, Connie R., additional, Verheul, Henk M.W., additional, and Labots, Mariette, additional

Published
2021
Full Text
View/download PDF

46. Clinical Predictors of Early Trial Discontinuation for Patients Participating in Phase I Clinical Trials in Oncology

Author

Douma, Joeri A. J., primary, Buffart, Laurien M., additional, Sedhom, Ramy, additional, Labots, Mariette, additional, Menke-van der Houven van Oordt, Willemien C., additional, Skardhamar, Mikkjal, additional, De Felice, Anthony, additional, Lee, Esther, additional, Dharmaraj, Divya, additional, Azad, Nilofer S., additional, Carducci, Michael A., additional, and Verheul, Henk M. W., additional

Published
2021
Full Text
View/download PDF

48. Endocriene bijwerkingen van checkpointremmers

Author

Chen, Weena J Y, Krul-Poel, Yvonne H M, Roth, Chantal, Labots, Mariette, van den Eertwegh, Alfons J M, Dreijerink, Koen M A, Internal medicine, Medical oncology, CCA - Cancer biology and immunology, and Amsterdam Gastroenterology Endocrinology Metabolism

Abstract

Checkpoint inhibition has emerged as a promising therapeutic strategy for several types of cancer. Immune-related adverse effects (irAEs) commonly involve the endocrine system. Distinguishing endocrine side effect-related symptoms from disease progression or treatment-related toxicity can be challenging. If not recognized in time, endocrine irAEs may be life-threatening. As the use of checkpoint inhibitors is expected to increase, there is a need for more awareness of endocrine irAEs amongst health care professionals. We describe three cases that illustrate the importance of timely recognition, patient education and the management of endocrinopathies. Two patients who were treated with the checkpoint inhibitor ipilimumab developed hypophysitis and subsequent episodes of hypocortisolism. These cases underline both the frequency of diagnostic delay and the importance of patient education with regard to glucocorticoid stress dosage. The third patient presented with diabetes mellitus after administration of nivolumab. A multidisciplinary approach is warranted to ensure optimal care for patients with endocrine irAEs.

Published
2019

49. Kinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome

Author

Labots, Mariette, primary, Pham, Thang V., additional, Honeywell, Richard J., additional, Knol, Jaco C., additional, Beekhof, Robin, additional, de Goeij-de Haas, Richard, additional, Dekker, Henk, additional, Neerincx, Maarten, additional, Piersma, Sander R., additional, van der Mijn, Johannes C., additional, van der Peet, Donald L., additional, Meijerink, Martijn R., additional, Peters, Godefridus J., additional, van Grieken, Nicole C.T., additional, Jiménez, Connie R., additional, and Verheul, Henk M.W., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results